SLU-PP-332 is an experimental “exercise mimetic” compound that activates estrogen-related receptors (ERRs) and is being researched for its potential to treat metabolic diseases, including obesity, type 2 diabetes, and heart failure.

Key benefits:

• Weight Loss and Fat Reduction: Treated obese mice gained significantly less fat mass and lost overall body weight, despite no change in diet or physical activity levels. The drug increases energy expenditure and speeds up body fat metabolism.
• Enhanced Endurance and Muscle Function: The compound leads to muscle adaptations that mirror endurance training, such as increased mitochondrial content and the development of fatigue-resistant muscle fibers, resulting in improved running endurance.
• Improved Metabolic Health: SLU-PP-332 improves glucose control and insulin sensitivity, suggesting potential for treating type 2 diabetes and metabolic syndrome.
  Mitochondrial Biogenesis: It enhances mitochondrial function and density in energy-demanding tissues like skeletal muscle, heart, and liver, which improves cellular energy production and efficiency.
• Potential Organ Protection: Studies suggest the compound could have protective effects against nonalcoholic fatty liver disease (NAFLD/NASH), kidney disease, and heart failure by improving organ metabolism and reducing inflammation.
• Neurological Benefits: Research is exploring its potential for treating cognitive dysfunction and neurodegenerative conditions like Alzheimer’s disease by countering damaging processes in the brain.

How to use:

Dosing protocols for men and female 200-800 mcg per day.